Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Vitamin E sequestration by liver fat in humans
Pierre-Christian Violet, … , Maret G. Traber, Mark Levine
Pierre-Christian Violet, … , Maret G. Traber, Mark Levine
Published December 10, 2019
Citation Information: JCI Insight. 2020;5(1):e133309. https://doi.org/10.1172/jci.insight.133309.
View: Text | PDF
Clinical Medicine Hepatology Metabolism

Vitamin E sequestration by liver fat in humans

  • Text
  • PDF
Abstract

BACKGROUND We hypothesized that obesity-associated hepatosteatosis is a pathophysiological chemical depot for fat-soluble vitamins and altered normal physiology. Using α-tocopherol (vitamin E) as a model vitamin, pharmacokinetics and kinetics principles were used to determine whether excess liver fat sequestered α-tocopherol in women with obesity-associated hepatosteatosis versus healthy controls.METHODS Custom-synthesized deuterated α-tocopherols (d3- and d6-α-tocopherols) were administered to hospitalized healthy women and women with hepatosteatosis under investigational new drug guidelines. Fluorescently labeled α-tocopherol was custom-synthesized for cell studies.RESULTS In healthy subjects, 85% of intravenous d6-α-tocopherol disappeared from the circulation within 20 minutes but reappeared within minutes and peaked at 3–4 hours; d3- and d6-α-tocopherols localized to lipoproteins. Lipoprotein redistribution occurred only in vivo within 1 hour, indicating a key role of the liver in uptake and re-release. Compared with healthy subjects who received 2 mg, subjects with hepatosteatosis had similar d6-α-tocopherol entry rates into liver but reduced initial release rates (P < 0.001). Similarly, pharmacokinetics parameters were reduced in hepatosteatosis subjects, indicating reduced hepatic d6-α-tocopherol output. Reductions in kinetics and pharmacokinetics parameters in hepatosteatosis subjects who received 2 mg were echoed by similar reductions in healthy subjects when comparing 5- and 2-mg doses. In vitro, fluorescent-labeled α-tocopherol localized to lipid in fat-loaded hepatocytes, indicating sequestration.CONCLUSIONS The unique role of the liver in vitamin E physiology is dysregulated by excess liver fat. Obesity-associated hepatosteatosis may produce unrecognized hepatic vitamin E sequestration, which might subsequently drive liver disease. Our findings raise the possibility that hepatosteatosis may similarly alter hepatic physiology of other fat-soluble vitamins.TRIAL REGISTRATION ClinicalTrials.gov, NCT00862433.FUNDING National Institute of Diabetes and Digestive and Kidney Diseases and NIH grants DK053213-13, DK067494, and DK081761.

Authors

Pierre-Christian Violet, Ifechukwude C. Ebenuwa, Yu Wang, Mahtab Niyyati, Sebastian J. Padayatty, Brian Head, Kenneth Wilkins, Stacey Chung, Varsha Thakur, Lynn Ulatowski, Jeffrey Atkinson, Mikel Ghelfi, Sheila Smith, Hongbin Tu, Gerd Bobe, Chia-Ying Liu, David W. Herion, Robert D. Shamburek, Danny Manor, Maret G. Traber, Mark Levine

×

Figure 2

Plasma concentrations of d6- and d3-α-tocopherol and redistribution into lipoproteins in healthy women.

Options: View larger image (or click on image) Download as PowerPoint
Plasma concentrations of d6- and d3-α-tocopherol and redistribution into...
(A) Protocol sampling scheme. (B) At time 0 in 6 subjects, d6-α-tocopherol 5 mg (●) was administered IV and d3-α-tocopherol 5 mg (○) was administered orally, with plasma samples obtained over 72 hours. (C) Plasma samples in B, magnified time interval –2 to 8 hours. (D) Percentage enrichment of d6-α-tocopherol (▲, HDL; ■, LDL; ●, VLDL) in lipoproteins following administration of 5 mg at time 0 in 6 subjects. (E) Percentage enrichment of d3-α-tocopherol (Δ, HDL; □, LDL; ○, VLDL) in lipoproteins following administration of 5 mg at time 0 in 6 subjects. Because HDL and LDL points were superimposed, for clarity HDL and LDL curves were slightly offset on the y axis. (F) Percentage of recovery of d3-α-tocopherol (○) and d6-α-tocopherol (■) in all lipoproteins compared with plasma concentrations in 6 subjects. (G) Distribution of 7 μM of d6-α-tocopherol in lipoproteins over time ex vivo (Δ, HDL; □, LDL; ○, VLDL). (H) At time 0 in 6 subjects, d6-α-tocopherol 5 mg (●) and 2 mg (●) was administered IV, with plasma samples obtained over 72 hours; inset: initial rates of d6-α-tocopherol reappearance for these 2 doses. SL, slope: 0.195 μM/h for 5-mg dose and 0.083 μM/h for 2-mg dose. Data represented as mean ± SEM. n = 6 for HS and n = 10 for healthy cohorts.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts